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ABSTRACT
The diagnosis of pancreatic cancer is devastating, with mortality rates nearing its incidence rates. To date, there are no effective targeted anti-pancreatic cancer therapeutics. We propose experiments that will explore function of an essential regulator of pancreatic development, the nuclear receptor LRH-1, in pancreatic cancer cells. Our target protein, LRH-1 receptor, is known to control not just one but multiple regulatory mechanisms essential for tumor growth and spread. We propose to find selective and potent compounds that inhibit LRH-1 activity in human pancreatic cancer cells, blunting their growth, proliferation and spread. The identified novel inhibitors of LRH-1 could then be developed into a pharmaceutical that will inhibit growth and proliferation of cancer cells in pancreatic tumors. As was proposed in our application, we performed computational filtering of over 5 million compounds and tested top ranked hits in the following biophysical and cell biology assays.
Virtual screening was performed against a constructed model of an inactive state of hLRH-1 LBD, as described in our recently published research article by Benod et al (1) . For computational docking experiments, we used a library of 5.2 million commercially available molecules from the ZINC database. Following visual inspection of the resulting top-ranked 500 compounds (~0.01% of the initial library content), twelve molecules were selected for experimental evaluations.
From these verification experiments, we identified two compounds - Transcription assay: To verify that these compounds not only bind LRH-1 but also deactivate the receptor upon binding, the transcriptional activity of LRH-1 was assessed in the absence and the presence of Cpd (3) and Cpd (3d2). These experiments showed that treatments with each individual compound lowered the levels of mRNA for G0S2 gene (a transcriptional target of LRH-1) (Fig. 3) ; the corresponding IC50 values were determined to be 5 ± 1 µM (Fig. 3A) and 6 ± 1 µM (Fig. 3B) . To prove that the observed effects by compounds are LRH-1 mediated, the analogous experiments were performed in non-induced HEK293 cells, which do not express the receptor; under these conditions, no significant changes in the levels of G0S2 transcripts were detected in cells treated with either compound compared to the control (1).
Assessing specificity of Cpd (3) and Cpd (3d2):
We examined whether the identified LRH-1 inhibitors exert any effects on transcriptional activities of other nuclear receptors. Using previously published methods, transactivation by three different nuclear receptors -steroidogenic factor 1 (SF-1, a close structural and functional analogue of LRH-1) as well as more distant thyroid hormone receptor beta (TRβ) and androgen receptor (AR) -was assessed in the absence and the presence of Cpd (3) and (3d2). These transcriptional studies presented no evidence of any specific, probe-mediated changes in the transcriptional activities of any of the tested receptors (1) . Based on these data, we conclude that the identified inhibitors bind to the LRH-1 receptor and inhibit its transcriptional activity preferentially.
Aim 2 (Task 2): Testing LRH-1 inhibitors in pancreatic cancer cells.
Because multiple LRH-1 gene targets (including cyclin E1 (Cyc E1), cyclin D1 (Cyc D1) and C-Myc genes) are known to control cell growth and proliferation, we investigated whether treatments of cells with the identified receptor antagonist affects cell proliferation in vitro (Task 2a). Our previous work (2) demonstrated that selective inhibition of LRH-1 transcription by siRNA arrests growth and proliferation of human pancreatic cancer cells. This receptor-mediated anti-proliferative effect was observed in four different pancreatic ductal adenocarcinoma (PDAC) cell lines, including AsPC-1, which express high levels of LRH-1 (2). Our current work shows that treatments of AsPC-1 cells with Cpd (3) and (3d2) result in a similar, dose-dependent inhibition of cell proliferation ( Fig. 4A, B ; concentrations of Cpd (3) and Cpd (3d2) associated with ~50% inhibition of cell proliferation are indicated).
Notably, no significant anti-proliferative effects were observed in pancreatic cancer cells L3.3 (Fig. 4C, D) that do not express LRH-1 receptor at a detectable level (2) . In concert with these data, inhibition of transcription of LRH-1 target genes NR0B2 and CCNE1 (encoding SHP and Cyclin E1, in light and dark gray, Fig. 4E, F) was detected in AsPC-1 but not in L3.3 cells following these treatments (Task 2b). No general cytotoxicity was encountered for either compound at the concentrations used for these experiments (1). These results support the idea that the observed anti-proliferative effects of the probes are receptor-mediated and specific. Our work demonstrates that human pancreatic ductal adenocarcinoma (PDAC) cells expressing LRH-1 are sensitive to treatments with the receptor specific inhibitors, and that growth and proliferation of LRH-1 positive cancer cells could be markedly decreased following such treatments.
The structure-based identification and characterization of the first LRH-1 specific antagonists is described in our recently published research article by Benod et al (1) . This paper reports the use of existing technologies but presents the first specific and potent compounds deriving from computational docking to a non-native protein target structure.
Through ongoing SAR (structure-activity relationship) studies in the PI's lab, we are optimizing the properties of the current LRH-1 antagonists (Aim 3 of the proposal, Task 3 of SOW). The goal of this program is to enhance the binding affinities and thus the therapeutic potential of LRH-1 antagonists without compromising their specificity.
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